^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    VAV1 mutation

    i
    Other names: VAV1, Vav Guanine Nucleotide Exchange Factor 1, Vav 1 Guanine Nucleotide Exchange Factor, Proto-Oncogene Vav, Vav 1 Oncogene, VAV,
    Entrez ID:
    7409
    over3years
    Characterization of the spectrum of trivalent VAV1-mutation-driven tumors using a gene-edited mouse model. (PubMed, Mol Oncol)
    These data indicate that VAV1 mutations play critical, although highly cell-type-specific, roles in tumorigenesis. They also indicate that such functions are contingent on the mutational landscape of the tumors involved.
    Preclinical • Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • VAV1 (Vav Guanine Nucleotide Exchange Factor 1)
    |
    VAV1 mutation
    4years
    Cancer-associated mutations in VAV1 trigger variegated signaling outputs and T-cell lymphomagenesis. (PubMed, EMBO J)
    This process requires the concurrent engagement of two downstream signaling branches that promote the chronic activation and transformation of follicular helper T cells. Collectively, these data reveal the genetic constraints associated with the lymphomagenic potential of VAV1 mutant subsets, similarities with other PTCL driver genes, and potential therapeutic vulnerabilities.
    Journal
    |
    RAC1 (Rac Family Small GTPase 1) • VAV1 (Vav Guanine Nucleotide Exchange Factor 1)
    |
    VAV1 mutation
    over4years
    Characteristics of genetic alterations of peripheral T-cell lymphoma in childhood including identification of novel fusion genes: the Japan Children's Cancer Group (JCCG). (PubMed, Br J Haematol)
    Conversely, alterations of PCDHGA4, ADAR, CUL9 and TP53 were identified only in EBV PTCL. Our observations suggest a clear difference in the molecular mechanism of onset between paediatric and adult PTCL and a difference in the characteristics of genetic alterations between EBV and EBV paediatric PTCL.
    Clinical • Journal
    |
    TP53 (Tumor protein P53) • NRAS (Neuroblastoma RAS viral oncogene homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • TET2 (Tet Methylcytosine Dioxygenase 2) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • STAT3 (Signal Transducer And Activator Of Transcription 3) • STAG2 (Stromal Antigen 2) • JAK3 (Janus Kinase 3) • ZFHX3 (Zinc Finger Homeobox 3) • ADAR (Adenosine Deaminase RNA Specific) • AFF2 (AF4/FMR2 family member 2) • GATA3 (GATA binding protein 3) • VAV1 (Vav Guanine Nucleotide Exchange Factor 1)
    |
    NRAS mutation • CDKN2A deletion • JAK3 mutation • VAV1 mutation